Drugs & Aging

, Volume 27, Issue 7, pp 545–558 | Cite as

Optimal Management of Peptic Ulcer Disease in the Elderly

  • Alberto Pilotto
  • Marilisa Franceschi
  • Stefania Maggi
  • Filomena Addante
  • Daniele Sancarlo
Review Article


Recent data report that the incidence of peptic ulcer is decreasing in the general population; conversely, the rates of gastric and duodenal ulcer hospitalization and mortality remain very high in older patients. Two major factors that might explain this epidemiological feature in the elderly population are the high prevalence of Helicobacter pylori infection and the increasing prescriptions of gastroduodenal damaging drugs, including NSAIDs and/or aspirin (acetylsalicylic acid). The main goals for treating peptic ulcer disease in old age are to reduce recurrence of the disease and to prevent complications, especially bleeding and perforation. The available treatments for peptic ulcer are essentially based on gastric acid suppression with antisecretory drugs and the eradication of H. pylori infection. The aim of this article is to report the available data on clinical efficacy and tolerability of peptic ulcer treatments in elderly patients and provide recommendations for their optimal use in this special population.

Proton pump inhibitor (PPI)-based triple therapies for 7 days are highly effective for the cure of H. pylori-positive peptic ulcers as well as for reducing ulcer recurrence. Antisecretory drugs are also the treatment of choice for NSAID- or aspirin-related peptic ulcers and are useful as preventive therapy in chronic users of NSAIDs and low-dose aspirin as antiplatelet therapy. Antisecretory PPI therapy has a favourable tolerability profile in geriatric patients; however, monitoring is suggested in older patients with frequent pulmonary infections, gastrointestinal malabsorption, unexplained chronic diarrhoea, osteoporosis or those taking concomitant cytochrome P450 2C19-metabolized medications.

The overall approach to the geriatric patient should include a comprehensive geriatric assessment that ensures multidimensional evaluation of the patient in order to better define the clinical risk of adverse outcomes in the older patient with peptic ulcer and its complications.


Peptic Ulcer Proton Pump Inhibitor Pylorus Infection Clarithromycin Triple Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Guralnik JM, Ferrucci L. Demography and epidemiology. In: Halter JB, Ouslander JG, Tinetti ME, et al., editors. Hazzard’s geriatric medicine and gerontology. 6th ed. New York: McGraw Hill, 2009: 45–67Google Scholar
  2. 2.
    Pilotto A, Malfertheiner P. Review article: an approach to Helicobacter pylori infection in the elderly. Aliment Pharmacol Ther 2002; 16: 683–91PubMedCrossRefGoogle Scholar
  3. 3.
    Pilotto A, Franceschi M, Di Mario F. Helicobacter pylori-associated peptic ulcer disease in elderly patients. Clin Geriatr 2000; 8: 49–58Google Scholar
  4. 4.
    Hilton D, Iman N, Burke GJ, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001; 96: 380–4PubMedCrossRefGoogle Scholar
  5. 5.
    Pilotto A, Maggi S, Noale M, et al., on behalf of the IPOD Investigators. Development and validation of a new questionnaire for the evaluation of upper gastrointestinal symptoms in the elderly population: a multicenter study. J Gerontol A Biol Sci Med Sci 2010; 65: 174–8PubMedCrossRefGoogle Scholar
  6. 6.
    Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in the elderly: a study of 840 consecutive patients. J Am Geriatr Soc 2006; 54: 1537–42PubMedCrossRefGoogle Scholar
  7. 7.
    Malfertheiner P, Chan FKL, McColl EL. Peptic ulcer disease. Lancet 2009; 374: 1449–61PubMedCrossRefGoogle Scholar
  8. 8.
    Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nature Clin Pract Gastroenterol Hepatol 2006; 3: 80–9CrossRefGoogle Scholar
  9. 9.
    Pilotto A. Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies. Drugs Aging 2001; 18: 487–94PubMedCrossRefGoogle Scholar
  10. 10.
    Ford A, Delaney B, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004; (4): CD003840Google Scholar
  11. 11.
    Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772–81PubMedCrossRefGoogle Scholar
  12. 12.
    Pilotto A, Franceschi M, Perri F, et al. Treatment options for Helicobacter pylori in the elderly. Aging Health 2006; 2: 661–8CrossRefGoogle Scholar
  13. 13.
    Tong JL, Ran ZH, Shen J, et al. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009; 34: 41–53PubMedCrossRefGoogle Scholar
  14. 14.
    Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005; 21: 1419–24PubMedCrossRefGoogle Scholar
  15. 15.
    Gisbert JP, Calvet X, O’Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313–25PubMedCrossRefGoogle Scholar
  16. 16.
    Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35–44PubMedCrossRefGoogle Scholar
  17. 17.
    Sharara AI, Chaar HF, Racoubian E, et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004; 9: 255–61PubMedCrossRefGoogle Scholar
  18. 18.
    Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2004; 20: 1181–8PubMedCrossRefGoogle Scholar
  19. 19.
    Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808–25PubMedCrossRefGoogle Scholar
  20. 20.
    Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553–62PubMedGoogle Scholar
  21. 21.
    Pilotto A, Franceschi M, Leandro G, et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Aliment Pharmacol Ther 2001; 15: 1031–6PubMedCrossRefGoogle Scholar
  22. 22.
    Moshkowitz M, Brill S, Konikoff FM, et al. The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive patients with dyspepsia. J Am Geriatr Soc 1999; 47: 720–2PubMedGoogle Scholar
  23. 23.
    Pilotto A, Franceschi M, Leandro G, et al. Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J Gastroenterol Hepatol 1999; 14: 464–71Google Scholar
  24. 24.
    Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 2002; 136: 13–24PubMedGoogle Scholar
  25. 25.
    Pilotto A, Rassu M, Leandro G, et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000; 32: 763–8PubMedCrossRefGoogle Scholar
  26. 26.
    Parsons HK, Carter MJ, Sanders DS, et al. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001; 15: 1473–8PubMedCrossRefGoogle Scholar
  27. 27.
    Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088–94PubMedCrossRefGoogle Scholar
  28. 28.
    Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312–9PubMedCrossRefGoogle Scholar
  29. 29.
    Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027–31PubMedGoogle Scholar
  30. 30.
    Padol S, Yuan YH, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467–75PubMedCrossRefGoogle Scholar
  31. 31.
    Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is a major predictor of treatment failure in White patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201–32PubMedCrossRefGoogle Scholar
  32. 32.
    Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 1479–84PubMedCrossRefGoogle Scholar
  33. 33.
    Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564–73PubMedCrossRefGoogle Scholar
  34. 34.
    Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521–8PubMedCrossRefGoogle Scholar
  35. 35.
    Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008; 47: 1–6PubMedCrossRefGoogle Scholar
  36. 36.
    Pilotto A, Addante F, D’Onofrio G, et al. The comprehensive geriatric assessment and the multidimensional approach: a new look at the older patient with gastroenterological disorders. Best Pract Clin Res Gastroenterol 2009; 23: 829–37CrossRefGoogle Scholar
  37. 37.
    Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498–506PubMedCrossRefGoogle Scholar
  38. 38.
    Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818–28PubMedCrossRefGoogle Scholar
  39. 39.
    Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8PubMedCrossRefGoogle Scholar
  40. 40.
    Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6PubMedCrossRefGoogle Scholar
  41. 41.
    Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on non-steroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Non-Steroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103: 2908–18PubMedCrossRefGoogle Scholar
  42. 42.
    Leandro G, Pilotto A, Franceschi M, et al. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924–36PubMedCrossRefGoogle Scholar
  43. 43.
    Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091–7PubMedCrossRefGoogle Scholar
  44. 44.
    Pilotto A, Franceschi M, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other nonsteroidal antiinflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res 2003; 15: 494–9PubMedGoogle Scholar
  45. 45.
    Pilotto A, Franceschi M, Longo MG, et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis 2004; 36: 666–70PubMedCrossRefGoogle Scholar
  46. 46.
    Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26: 265–75PubMedCrossRefGoogle Scholar
  47. 47.
    Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007; 24: 121–31PubMedCrossRefGoogle Scholar
  48. 48.
    Pilotto A, Di Mario F, Franceschi M, et al. Pantoprazole versus one-week H. pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000; 14: 1077–82PubMedCrossRefGoogle Scholar
  49. 49.
    Chan FKL, Chung SCS, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967–73PubMedCrossRefGoogle Scholar
  50. 50.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRefGoogle Scholar
  51. 51.
    CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996; 348: 1329–39CrossRefGoogle Scholar
  52. 52.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502PubMedCrossRefGoogle Scholar
  53. 53.
    Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218–24PubMedGoogle Scholar
  54. 54.
    Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827–30PubMedCrossRefGoogle Scholar
  55. 55.
    Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 2000; 321: 1183–7PubMedCrossRefGoogle Scholar
  56. 56.
    McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel randomized controlled trials. Am J Med 2006; 199: 624–38CrossRefGoogle Scholar
  57. 57.
    Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413–6PubMedCrossRefGoogle Scholar
  58. 58.
    Pilotto A, Franceschi M, Leandro G, et al. Helicobacter pylori infection and the risk of gastroduodenal damage in symptomatic elderly chronic low-dose aspirin users: effect of antisecretory drugs. Age Ageing 2004; 33: 402–4PubMedCrossRefGoogle Scholar
  59. 59.
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033–8PubMedCrossRefGoogle Scholar
  60. 60.
    Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119–25PubMedCrossRefGoogle Scholar
  61. 61.
    Chan FK, Chinh JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238–44PubMedCrossRefGoogle Scholar
  62. 62.
    Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 860–5PubMedCrossRefGoogle Scholar
  63. 63.
    Ho PM, Maddox T, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937–44PubMedCrossRefGoogle Scholar
  64. 64.
    Lanas A, García-Rodríguez LA, Arroyo MT, et al., Investigators of the Asociación Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507–15PubMedCrossRefGoogle Scholar
  65. 65.
    Lanza F, Rack MF, Simon TJ, et al. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998; 93: 753–7PubMedCrossRefGoogle Scholar
  66. 66.
    Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631–8PubMedCrossRefGoogle Scholar
  67. 67.
    Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs: comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92: 1322–5PubMedGoogle Scholar
  68. 68.
    Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77: 1031–43PubMedCrossRefGoogle Scholar
  69. 69.
    Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal anti-inflammatory drug therapy. J Gastroenterol 2009; 44: 113–20PubMedCrossRefGoogle Scholar
  70. 70.
    Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006; 119: 719–27PubMedCrossRefGoogle Scholar
  71. 71.
    Vidal X, Ibáñez L, Vendrell L, et al., Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31: 159–68PubMedCrossRefGoogle Scholar
  72. 72.
    Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475–82PubMedCrossRefGoogle Scholar
  73. 73.
    Pilotto A, Franceschi M. Upper gastrointestinal disorders. In: Halter JB, Ouslander JG, Tinetti ME, et al., editors. Hazzard’s geriatric medicine and gerontology. 6th ed. New York: McGraw Hill, 2009: 1075–90Google Scholar
  74. 74.
    Hung C, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005; 128: 1845–50PubMedCrossRefGoogle Scholar
  75. 75.
    Andriulli A, Annese V, Caruso N, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol 2005; 100: 207–19PubMedCrossRefGoogle Scholar
  76. 76.
    Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–21PubMedCrossRefGoogle Scholar
  77. 77.
    Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318–21PubMedCrossRefGoogle Scholar
  78. 78.
    Masaoka T, Suzuki H, Hori S, et al. Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention. J Gastroenterol Hepatol 2007; 22: 1404–8PubMedCrossRefGoogle Scholar
  79. 79.
    Romagnuolo J, Barkun AN, Enns R, et al. Simple clinical predictors may obviate urgent endoscopy in selected patients with nonvariceal upper gastrointestinal tract bleeding. Arch Intern Med 2007; 167: 265–70PubMedCrossRefGoogle Scholar
  80. 80.
    Stanley AJ, Ashley D, Mowat C, et al. Outpatient management of patients with low-risk upper gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 2009; 373: 42–7PubMedCrossRefGoogle Scholar
  81. 81.
    Cooper GS, Kou TD, Wong RCK. Outpatient management of nonvariceal upper gastrointestinal hemorrhage: unexpected mortality in Medicare beneficiaries. Gastroenterology 2009; 136: 108–14PubMedCrossRefGoogle Scholar
  82. 82.
    Pilotto A, Ferrucci L, Scarcelli C, et al. Usefulness of the comprehensive geriatric assessment in older patients with upper gastrointestinal bleeding: a two-year follow-up study. Dig Dis 2007; 25: 124–8PubMedCrossRefGoogle Scholar
  83. 83.
    Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418–23PubMedCrossRefGoogle Scholar
  84. 84.
    Dial S, Delaney C, Schneider V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175: 745–8PubMedGoogle Scholar
  85. 85.
    Pilotto A, Franceschi M, Vitale D, et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 2008; 103: 2816–23PubMedCrossRefGoogle Scholar
  86. 86.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infections in patients taking acid suppression therapy. Am J Gastroenterol 2007; 102: 2047–56PubMedCrossRefGoogle Scholar
  87. 87.
    Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772–8PubMedCrossRefGoogle Scholar
  88. 88.
    Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784–90PubMedCrossRefGoogle Scholar
  89. 89.
    Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955–60PubMedCrossRefGoogle Scholar
  90. 90.
    Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950–5PubMedCrossRefGoogle Scholar
  91. 91.
    Sarkar M, Hennessy S, Yang YX. Proton pump inhibitor use and the risk of community-acquired pneumonia. Ann Intern Med 2008; 149: 391–8PubMedGoogle Scholar
  92. 92.
    Schenk BE, Festen HP, Kuipers EJ, et al. Effect of short-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996; 10: 541–5PubMedCrossRefGoogle Scholar
  93. 93.
    den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491–7CrossRefGoogle Scholar
  94. 94.
    Yang Y, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947–53PubMedCrossRefGoogle Scholar
  95. 95.
    Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 12: 319–26Google Scholar
  96. 96.
    Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952–60PubMedCrossRefGoogle Scholar
  97. 97.
    Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the women’s health initiative. Arch Intern Med 2010; 170: 765–1PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Alberto Pilotto
    • 1
  • Marilisa Franceschi
    • 2
  • Stefania Maggi
    • 3
  • Filomena Addante
    • 1
  • Daniele Sancarlo
    • 1
  1. 1.Geriatric Unit and Gerontology-Geriatrics Research Laboratory, Department of Medical SciencesIRCCS Casa Sollievo della SofferenzaSan Giovanni Rotondo (FG)Italy
  2. 2.Endoscopy Unit, Department of SurgeryASL Alto VicentinoSchio (VI)Italy
  3. 3.CNR Aging SectionPadovaItaly

Personalised recommendations